Glenmark Pharma receives warning letter from USFDA for Indore facility
INSUBCONTINENT EXCLUSIVE:
Glenmark Pharmaceuticals has announced that it received a warning letter from the U.S
Food and Drug Administration (FDA) for its manufacturing facility in Indore, Madhya Pradesh, India.
